The aim of this research is to evaluate the outcome of treatment of bone cysts in the proximal femur at the LUMC and other collaboration centers from EMSOS and EPOS community. Special focus will be on the duration of partial weight bearing and functional restrictions, radiographic healing of the bone cyst after treatment and complications of the treatment, like (re-)fracture, infection and recurrence. This international, retrospective, multi-centre trial, with the aim to give an overview and comparison of all the different treatment modalities used in treating unicameral and aneurysmal bone cysts in children.
Deadline: September 1st 2020
Contact
Michiel van der Sande, Leiden
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Download
Bone cyste global cohort.pdf3.83 MB
Researchprotocol bone cysts.pdf955.18 KB
Aim of this study is to analyse the modalities of diagnosis of LR in high-grade osteosarcoma, pattern of recurrence, treatment of LR and factors influencing post-LR survival (PLRS) focusing on the role of second line chemotherapy, margins and type of surgery
Contact
Emanuela Palmerini, Bologna
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadSynopsis OSTEO LR.pdf613.67 KB
Unicameral bone cysts (UBC), also called simple bone cysts, Aneurysmal bone cysts (ABC) (and Fibrous Dysplasia (FD) lesions) can present as benign fluid filled cavities that can enlarge over time, leading to thinning and with that weakening of the bone. Both bone cysts and FD predominantly occur in children and adolescents, with a peak age between 3 and 14 years [1-3]. The annual prevalence and incidence are both estimated at ±0.3 per 100.000 people for UBC [4, 5]. For ABC, the annual prevalence is estimated at ±0.3, with an annual incidence ranging from 0.14 to 0.54 per 100.000 people [1, 4-6]. However, the true prevalence and incidence is difficult to estimate due to clinically silent cases and spontaneous regression. For the same reason the incidence and prevalence of FD is unknown and no estimation is given in literature.
Contact
Michiel van de Sande (Leiden)
This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsResearchprotocol bone cysts EPOS anf EMOS May 27 2019.pdf569.87 KB
Dear colleagues, hereby we invite you to participate in a multicentric retrospective study “Tumors at the elbow –
clinical and oncological results after resection and endoprosthesis replacement”.
Bone and soft tissue tumors involving the elbow are very rare. There is a limited knowledge about
clinical and oncological results of distal humerus and/or proximal ulna resection and endoprosthetic elbow
reconstruction: in the last two decades only a few publications analyzed this problem, including per study
at average about 20 patients. These studies include numerous various parameters (different implants,
various diagnosis…), making the task of summarizing the results not easy.
Contact
Dr. Marko Bergovec
This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsElbow TM-invitation.pdf141.66 K
Malignancy during pregnancy is a very rare entity with an estimated incidence of 1/1000 pregnancies.
Individual therapeutic customization is the only choice of treatment with respect to the health of the
mother, and her child.
The occurrence of sarcoma during pregnancy is even more exceptional, with about 140 reported cases
in the accessible literature. 60% is reported as primary soft tissue sarcomas, 40% as primary bone
sarcomas. No true systematic study has been undertaken to investigate the whole diagnostic,
therapeutic and prognostic concept of these sarcomas during pregnancy as an ‘entity’.
Contact
University Department of Experimental Pathology, Vrije Universiteit Brussel, Belgium.
Prof. dr. Ramses Forsyth, director (This email address is being protected from spambots. You need JavaScript enabled to view it.).
DownloadsEMSOS study Sarcoma during Pregnancy.pdf136.25 KB
Over the last 20 years, expandable prostheses have made a significant impact on the reconstruction methods we routinely use in children with bone tumors.[1-4] Although these implants are expensive and associated with a high complication rate [5-9], even in experienced hands, they are considered the main reconstructive option for children in a certain age group and for selected bone segments.
Contact
Eric Staals
This email address is being protected from spambots. You need JavaScript enabled to view it.
Musculoskeletal Oncology Department
Istituto Ortopedico Rizzoli, Bologna, Italy
DownloadsEMSOS study on expandable distal femoral megaprostheses.pdf190.02 KB
Fibroma of bone is a rare, locally aggressive bone tumor. Once it was called the osseous counterpart of extra-abdominal desmoid tumor, because of the histological aspects. In 2013, the WHO described the microscopic appearance of desmoplastic fibroma as being composed of slender, spindle to stellate cells with minimal cytological atypia and abundant collagenous matrix.
Contact:
Frank Traub MD, PhD | This email address is being protected from spambots. You need JavaScript enabled to view it.
Dimosthenis Andreou, M.D. | This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsDesmoplastic Fibroma of bone.pdf135.88 KB
Desmoplastic Fibroma EMSOS study datasheet.xls48.00 KB
Desmoid-type fibromatosis is an intermediate soft tissue tumour (WHO) with clonal fibroblastic proliferation originating in the deep soft tissues. It is characterised by local infiltration without metastatic potential. In the past decades resectable masses have been mainly treated surgically with a high incidence of local recurrence in up to one third of the patients independently from resection margins. Local recurrence negative prognostic factors after surgery have been identified in younger age, female gender, distal limb location and recurrent disease.
Alternative management including radioterapy or medical treatment with NSAIDS, hormone therapy, chemotherapy and tyrosine kinase inhibitors led to high recurrence rate as well.
As a consequence in recent years the wait and see approach, with strict and close clinical and instrumental monitoring of the involved site has gained popularity as first line management for silent masses not involving neurovascular bundles.
Contact: Prof Domenico Andrea Campanacci | This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsEMSOS Fibromatosis study.pdf131.83 KBEMSOS database.xls36.00 KB
Clear cell chondrosarcoma is a rare variant of chondrosarcoma, behaving as a low grade malignant bone tumor and characterized by a proliferation of tumor cells with clear cytoplasm.
Clear cell chondrosarcomas account for around 2% of all chondrosarcomas. They have been described in most bones of the body but usually affect the proximal epiphysis of the humerus or femur.
Contact
Doz. Dimosthenis Andreou, Münster, Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsClear cell chondrosarcoma EMSOS study 20170906.pdf90.27 KBClear cell chondrosarcoma EMSOS study protocol.xls36.00 KB
